Baird Medical Investment Holdings Ltd. reported preliminary unaudited financial results for the six months ended June 30, 2026, showing revenue of approximately $9.9 million, a 24.6% increase from $8.0 million in the prior year period. Gross profit rose 32.0% to $8.6 million with an improved gross margin of 87.0%, driven by geographic sales shifts and licensing revenue. Total operating expenses decreased significantly to $7.8 million from $17.0 million, primarily due to reductions in research and development and general administrative costs. The company achieved net income of approximately $14,000 compared to a net loss of $(11.4) million previously, alongside EBITDA of $1.6 million and adjusted EBITDA of $4.0 million. U.S. revenue contributed approximately 27% of the total, reflecting successful commercial expansion in key territories including Argentina, Vietnam, and Pakistan. Baird Medical is a global medical device company specializing in minimally invasive ablation technologies for solid tumors.